Current perspectives on camptothecins in cancer treatment.

por Dancey, J., Eisenhauer, E. A.
Publicado 1996

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

por Hospers, G A P, Eisenhauer, E A, Vries, E G E de
Publicado 1999

Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185

por Buckstein, R., Meyer, R.M., Seymour, L., Biagi, J., MacKay, H., Laurie, S., Eisenhauer, E.
Publicado 2007

Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group.

por Eisenhauer, E. A., Silver, H. K., Venner, P. M., Thirlwell, M. P., Weinerman, B., Coppin, C. M.
Publicado 1987

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.

por Evans, W. K., Eisenhauer, E., Hughes, P., Maroun, J. A., Ayoub, J., Shepherd, F. A., Feld, R.
Publicado 1988

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

por Razak, A R A, Hotte, S J, Siu, L L, Chen, E X, Hirte, H W, Powers, J, Walsh, W, Stayner, L-A, Laughlin, A, Novotny-Diermayr, V, Zhu, J, Eisenhauer, E A
Publicado 2011